ACTB-1003

ACTB-1003 is an oral kinase inhibitor that targets cancer mutations (inhibits FGFR), angiogenesis (inhibits VEGFR2 and Tie-2), and induces apoptosis (targets RSK and p70S6K downstream of PI3 kinase).
Supplier Alfa Cytology
Product # BC0443
Pricing 5.0 mg, 10.0 mg, inquire
Feedback